Tauns Laboratories, Inc. (197A) Price & Analysis

Compare

0 Followers

197A Stock Chart & Stats

¥509.00

¥4.00(0.67%)

At close: Jan 08 4:00 PM EST

¥509.00

¥4.00(0.67%)

Day’s Range― - ―

52-Week Range¥418.00 - ¥618.00

Previous CloseN/A

Volume864.10K

Average Volume (3M)400.80K

Market Cap

¥59.48B

Enterprise Value¥72.59B

Total Cash (Recent Filing)¥9.27B

Total Debt (Recent Filing)¥14.42B

Price to Earnings (P/E)15.6

Beta0.48

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield5.09%

Share Statistics

EPS (TTM)N/A

Shares Outstanding106,404,150

10 Day Avg. Volume355,040

30 Day Avg. Volume400,796

Financial Highlights & Ratios

PEG Ratio1.16

Price to Book (P/B)3.14

Price to Sales (P/S)2.94

P/FCF Ratio25.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Revenue ModelTauns' multi-channel revenue mix—direct sales, strategic pharma partnerships, licensing of proprietary tech and grant funding—reduces customer concentration and revenue risk. This structural diversity supports steadier cash inflows, funds R&D and commercialization, and enhances resilience over the medium term.

Strong Profitability MarginsReported high gross and net margins alongside robust EBIT and EBITDA indicate efficient operations and pricing power in its diagnostic and therapeutic lines. Durable margins provide internal funding capacity for R&D and commercial expansion, helping sustain competitiveness across product cycles.

Improving Cash GenerationSignificant improvement in free cash flow and a healthy operating cash flow-to-net-income ratio show better cash conversion. Consistent cash generation supports reinvestment, partnership execution and reduces reliance on external financing, improving medium-term financial flexibility.

Bears Say

Rising LeverageAn increase in total debt, even with a manageable debt-to-equity ratio today, raises longer-term financing and interest-rate exposure. Continued debt growth could constrain strategic flexibility, increase fixed financing costs, and limit capacity to invest in R&D or M&A during downturns.

Cash Flow VolatilityHistoric swings in operating and free cash flow, including a prior year of negative operating cash flow, indicate episodic liquidity risk. Persistent volatility may necessitate external financing or draw on credit lines, raising financing costs, dilution risk, and complicating long-term planning.

Emerging Cost PressureA slight decline in gross profit implies emerging cost or pricing pressure that could, if sustained, erode margins. For a biotech company reliant on healthy gross margins to fund R&D and commercialization, ongoing cost pressure would weaken reinvestment capacity and competitive positioning.

Tauns Laboratories, Inc. News

Tauns Laboratories Issues FY2026 Q2 Financial Highlights

The latest update is out from Tauns Laboratories, Inc. ( ($JP:197A) ). Tauns Laboratories, Inc. has released a...

4d ago

197A

Tauns Laboratories Profit Halves on Lower Sales but Keeps Full-Year Outlook and Dividend Plan

Tauns Laboratories, Inc. ( ($JP:197A) ) just unveiled an announcement. Tauns Laboratories reported a sharp year-on-year decline for...

4d ago

197A

TAUNS Laboratories Acquires CLAIRVO TECHNOLOGIES to Boost Diagnostic Innovations

The latest update is out from Tauns Laboratories, Inc. ( ($JP:197A) ). TAUNS Laboratories, Inc. has announced its...

3M ago

197A

Tauns Laboratories Faces Financial Decline but Projects Recovery

Tauns Laboratories, Inc. ( ($JP:197A) ) has provided an announcement. Tauns Laboratories, Inc. reported a significant decline in...

3M ago

197A

Tauns Laboratories Revises Dividend Forecast for FY 2026

An update from Tauns Laboratories, Inc. ( ($JP:197A) ) is now available. Tauns Laboratories, Inc. has announced a...

3M ago

197A

Tauns Laboratories Reports Modest Growth and Positive Outlook

Tauns Laboratories, Inc. ( ($JP:197A) ) has issued an update. Tauns Laboratories, Inc. reported its financial results for...

6M ago

197A

TAUNS Laboratories Withdraws Prime Market Application

An update from Tauns Laboratories, Inc. ( ($JP:197A) ) is now available. TAUNS Laboratories, Inc. has decided to...

7M ago

197A

TAUNS Laboratories’ Shares Selected for Loan Margin Trading

The latest announcement is out from Tauns Laboratories, Inc. ( ($JP:197A) ). TAUNS Laboratories, Inc. announced that its...

8M ago

197A

Tauns Laboratories Reports Growth in Nine-Month Financial Results

The latest announcement is out from Tauns Laboratories, Inc. ( ($JP:197A) ). Tauns Laboratories, Inc. reported a 7.6%...

9M ago

197A

TAUNS Laboratories Seeks Prime Market Listing on Tokyo Stock Exchange

Tauns Laboratories, Inc. ( ($JP:197A) ) has shared an announcement. TAUNS Laboratories, Inc. has applied to change its...

9M ago

197A

197A FAQ

What was Tauns Laboratories, Inc.’s price range in the past 12 months?

Tauns Laboratories, Inc. lowest stock price was ¥418.00 and its highest was ¥618.00 in the past 12 months.

What is Tauns Laboratories, Inc.’s market cap?

Tauns Laboratories, Inc.’s market cap is ¥59.48B.

When is Tauns Laboratories, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Tauns Laboratories, Inc.’s earnings last quarter?

Currently, no data Available

Is Tauns Laboratories, Inc. overvalued?

According to Wall Street analysts Tauns Laboratories, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tauns Laboratories, Inc. pay dividends?

Tauns Laboratories, Inc. pays a Annually dividend of ¥14 which represents an annual dividend yield of 5.09%. See more information on Tauns Laboratories, Inc. dividends here

What is Tauns Laboratories, Inc.’s EPS estimate?

Tauns Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tauns Laboratories, Inc. have?

Tauns Laboratories, Inc. has 106,404,150 shares outstanding.

What happened to Tauns Laboratories, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tauns Laboratories, Inc.?

Currently, no hedge funds are holding shares in JP:197A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tauns Laboratories, Inc.

TAUNS Laboratories, Inc. develops and manufactures vitro diagnostic drugs & measuring instruments. It also provides import and export of industrial measuring instruments, medical, physical, chemical and measuring instruments. The company was founded in April 1987 and is headquartered in Izunokuni, Japan.